Furthermore, upregulated miRNA signatures of miR-211-5p in melanoma and melanoma-derived vesicular secretome have been suggested as indicative of therapeutic resistance developed against BRAF inhibitors such as vemurafenib, used in treating metastatic melanomas [114]. This evidence concerns the gene BRAF and melanoma.